{"url_path":"/sec/dftx/8-k/2026-06-22/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 ****Regulation FD Disclosure.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-22","source_url":"https://www.sec.gov/Archives/edgar/data/1813814/0001104659-26-076091-index.html","accession_number":"0001104659-26-076091","cik":"0001813814","ticker":"DFTX","issuer_name":"Definium Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1813814/0001104659-26-076091-index.html","primary_entity_key":"0001813814","primary_entity_name":"Definium Therapeutics, Inc."},"word_count":167,"has_tables":true,"body_markdown":"**Item 7.01****Regulation FD Disclosure.**\n\n \n\nOn June 22, 2026, Definium Therapeutics, Inc. (the “Company”)\nissued a press release (the “Press Release”) announcing positive topline data from the Company’s Phase 3 Emerge study\nof DT120 ODT for the treatment of major depressive disorder. A copy of the Press Release is furnished as Exhibit 99.1 hereto, and\nis incorporated by reference into this Item 7.01.\n\n \n\nThe information furnished pursuant to this Item 7.01, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of\n1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed to\nbe incorporated by reference into any of the Company’s filings with the SEC under the Exchange Act or the Securities Act of 1933,\nas amended, whether made before or after the date hereof, regardless of any general incorporation language in such a filing, except as\nexpressly set forth by specific reference in such a filing."}